These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 20129447)

  • 21. Calcineurin inhibitors and nephrotoxicity in children.
    Liu F; Mao JH
    World J Pediatr; 2018 Apr; 14(2):121-126. PubMed ID: 29532435
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Maximizing the clinical outcome with mTOR inhibitors in the renal transplant recipient: defining the role of calcineurin inhibitors.
    Nashan B
    Transpl Int; 2004 Jul; 17(6):279-85. PubMed ID: 15221123
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New strategies to reduce nephrotoxicity.
    Kreis H
    Transplantation; 2001 Dec; 72(12 Suppl):S99-104. PubMed ID: 11833149
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
    Watson CJ; Gimson AE; Alexander GJ; Allison ME; Gibbs P; Smith JC; Palmer CR; Bradley JA
    Liver Transpl; 2007 Dec; 13(12):1694-702. PubMed ID: 18044728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stable graft function after reduction of calcineurin inhibitor dosage in paediatric kidney transplant patients.
    Plank C; Benz K; Amann K; Nüsken KD; Dittrich K; Rascher W; Sauerstein K; Stuppy A; Klare B; Dötsch J
    Nephrol Dial Transplant; 2006 Oct; 21(10):2930-7. PubMed ID: 16837512
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
    Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deciphering calcineurin inhibitor nephrotoxicity: a pharmacological approach.
    Pallet N; Legendre C
    Pharmacogenomics; 2010 Oct; 11(10):1491-501. PubMed ID: 21047207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reviewing the evidence for de novo immunosuppression with sirolimus.
    Flechner SM
    Transplant Proc; 2008 Dec; 40(10 Suppl):S25-8. PubMed ID: 19100902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential expression of tissue factor (TF) in calcineurin inhibitor-induced nephrotoxicity and rejection--implications for development of a possible diagnostic marker.
    Osterholm C; Veress B; Simanaitis M; Hedner U; Ekberg H
    Transpl Immunol; 2005 Dec; 15(2):165-72. PubMed ID: 16412961
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR; Augustine JJ; Krishnamurthi V; Goldfarb DA; Flechner SM; Braun WE; Hricik DE; Dennis VW; Poggio ED
    Transplantation; 2006 Aug; 82(3):368-74. PubMed ID: 16906035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients.
    Segundo DS; Ruiz JC; Izquierdo M; Fernández-Fresnedo G; Gómez-Alamillo C; Merino R; Benito MJ; Cacho E; Rodrigo E; Palomar R; López-Hoyos M; Arias M
    Transplantation; 2006 Aug; 82(4):550-7. PubMed ID: 16926600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for calcineurin inhibitor nephrotoxicity after renal transplantation: a systematic review and meta-analysis.
    Xia T; Zhu S; Wen Y; Gao S; Li M; Tao X; Zhang F; Chen W
    Drug Des Devel Ther; 2018; 12():417-428. PubMed ID: 29535503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.
    Yang YJ; Chen DZ; Li LX; Kou JT; Lang R; Jin ZK; Han DD; He Q
    Transplant Proc; 2008 Jun; 40(5):1541-4. PubMed ID: 18589147
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Calcineurin inhibitor nephrotoxicity in nephrotic syndrome].
    Ogahara S; Hisano S; Saito T
    Nihon Jinzo Gakkai Shi; 2011; 53(4):615-9. PubMed ID: 21688482
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatment of severe steroid-dependent nephrotic syndrome (SDNS) in children with tacrolimus.
    Sinha MD; MacLeod R; Rigby E; Clark AG
    Nephrol Dial Transplant; 2006 Jul; 21(7):1848-54. PubMed ID: 16311257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity.
    Campistol JM; Grinyó JM
    Transplantation; 2001 Jun; 71(11 Suppl):SS42-51. PubMed ID: 11583488
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Altitude and arteriolar hyalinosis after kidney transplantation.
    Cippà PE; Grebe SO; Fehr T; Wüthrich RP; Mueller TF
    Nephrology (Carlton); 2016 Sep; 21(9):782-4. PubMed ID: 26823025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytochrome P450 3A5 expression in the kidneys of patients with calcineurin inhibitor nephrotoxicity.
    Joy MS; Hogan SL; Thompson BD; Finn WF; Nickeleit V
    Nephrol Dial Transplant; 2007 Jul; 22(7):1963-8. PubMed ID: 17395652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Calcineurin inhibitor substitution with sirolimus vs. reduced-dose calcineurin inhibitor plus sirolimus is associated with improved renal dysfunction in heart transplant patients.
    Potter BJ; Giannetti N; Edwardes MD; Cecere R; Cantarovich M
    Clin Transplant; 2007; 21(3):305-8. PubMed ID: 17488377
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Conversion from calcineurin inhibitors to sirolimus in kidney transplant patients reduces the urinary transforming growth factor-beta1 concentration.
    Saurina A; Campistol JM; Lario S; Oppenheimer F; Diekmann F
    Transplant Proc; 2007 Sep; 39(7):2138-41. PubMed ID: 17889117
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.